Transient ischemic attack (TIA) or minor ischemic stroke has a high risk of early recurrent
stroke. As the golden standard, aspirin effect modestly on acute ischemic stroke, and
slightly increase the risk of intracerebral hemorrhage. Recently, edoxaban, a new oral
anticoagulant, is proved to be as effective as traditional anticoagulants, while carrying
significantly less risk of intracranial hemorrhage.
This trial is a randomized, double-blind, multicenter, controlled clinical trial in China.
The investigators will assess the hypothesis that a 30-days edoxaban regimen is superior to
aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular
event.